Scribble

Price Momentum

MRNA is trading near the bottom of its 52-week range and above its 200-day simple moving average.
Price change

The price of MRNA shares has decreased $0.21 since the market last closed. This is a 0.71% drop.
Opened at $29.16.

The stock opened $0.30 lower than its previous close.

Key terms

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Sector

Industry

Employees

Founded

Website

Key stock statistics

1-day range

52-week range

Market cap

P/E ratio

Next earnings date

Dividend yield

Ex-dividend date

Dividend pay date

Market cap: $11.51B

A market capitalization between $10 billion and $200 billion places MRNA in the large capitalization category.

Key terms

Smart score

Today 11:55am ET Option traders moderately bearish in Moderna with shares down 0.41% by TipRanks Today 8:26am ET Evercore ISI Reaffirms Their Hold Rating on Moderna (MRNA) by TipRanks Today 7:25am ET Moderna saus CHMP adopts positive opinion for mNEXSPIKE by TipRanks Dec 13, 2025 4:02am ET PayPal, SoundHound, Moderna, Devon, Bristol-Myers: Trending by Analysts by TipRanks Dec 12, 2025 9:41am ET Roblox downgraded, Lululemon upgraded: Wall Street’s top analyst calls by TipRanks Dec 12, 2025 8:25am ET Morgan Stanley Keeps Their Hold Rating on Moderna (MRNA) by TipRanks Dec 12, 2025 8:17am ET Moderna price target lowered to $28 from $30 at Morgan Stanley by TipRanks Dec 11, 2025 8:05pm ET Moderna’s Future: Balancing Growth Potential and Uncertainty with a Hold Rating by TipRanks Dec 11, 2025 8:00pm ET Moderna initiated with a Hold at Jefferies by TipRanks Dec 10, 2025 2:06pm ET Moderately bullish activity in Moderna with shares up 0.53% by TipRanks Dec 09, 2025 2:10pm ET FDA probe into COVID vaccines includes adults, Bloomberg reports by TipRanks Dec 09, 2025 2:05pm ET FDA to investigate COVID vaccine safety across age groups by TipRanks Dec 09, 2025 7:15am ET Moderna’s Growth Prospects: Balancing Revenue Potential and Legal Challenges by TipRanks Dec 08, 2025 1:30pm ET Mixed options sentiment in Moderna with shareslittle changed by TipRanks Dec 05, 2025 1:10pm ET Private Markets: Kalshi announces new funding at $11B valuation by TipRanks Dec 04, 2025 5:44pm ET SPY ETF Daily Update, 12/4/2025 by TipRanks Dec 03, 2025 6:20pm ET SPY ETF Daily Update, 12/3/2025 by TipRanks Dec 03, 2025 8:45am ET Vanguard S&P 500 ETF (VOO) Daily Update, 12/3/2025 by TipRanks Dec 02, 2025 5:33pm ET SPY ETF Daily Update, 12/2/2025 by TipRanks Dec 02, 2025 11:15am ET Moderna CFO says ‘doesn’t know’ what’s behind FDA claims on Covid vaccine deaths by TipRanks Dec 02, 2025 8:00am ET Vanguard S&P 500 ETF (VOO) Daily Update, 12/2/2025 by TipRanks Dec 02, 2025 6:56am ET Moderna (MRNA) Gets a Hold from Bernstein by TipRanks Dec 02, 2025 6:15am ET Vaccine committee considers changes to childhood schedule, NY Times reports by TipRanks Dec 01, 2025 1:55pm ET Moderna put volume heavy and directionally bearish by TipRanks Dec 01, 2025 11:43am ET MRNA, NVAX, BNTX: Here’s What Triggered a Sell-off in Major Vaccine Stocks Today by TipRanks Dec 01, 2025 11:20am ET Prasad email a headwind for vaccine manufacturers, says BofA by TipRanks Dec 01, 2025 9:11am ET Video: Vaccine makers slide following report of leaked memo from FDA’s Prasad by TipRanks Dec 01, 2025 9:05am ET Morning Movers: Synopsys leaps following Nvidia investment by TipRanks Dec 01, 2025 7:55am ET Prasad ties 10 children deaths to COVID vaccines in leaked memo, STAT reports by TipRanks Dec 01, 2025 7:07am ET Moderna (MRNA) Gets a Buy from Piper Sandler by TipRanks Nov 30, 2025 5:03am ET The Week That Was, The Week Ahead: Macro & Markets, November 30 by TipRanks

1-year income & revenue

Total revenue: $3.24B (1Y), $1.02B (Q3)

Total Revenue decreased 52.69% since last year and increased 615.49% since last quarter.
Net income: -$3.56B (1Y), -$200.00M (Q3)

Net Income increased 24.46% since last year and increased 75.76% since last quarter.
Earnings per share: -$9.27 (1Y), -$0.51 (Q3)

EPS increased 24.85% since last year and increased 75.88% since last quarter.

Key terms

analyst rating

buy
hold
sell

1-year stock price forecast

$ Market cap P/E ratio $ Price 1d change 52-week range

How competitors are chosen

MRNA's competitors are included in the Health Technology sector and Biotechnology group
Market cap: $11.51B

A market capitalization between $10 billion and $200 billion places MRNA in the large capitalization category.